JP2010540616A5 - - Google Patents

Info

Publication number

JP2010540616A5

JP2010540616A5 JP2010527565A JP2010527565A JP2010540616A5 JP 2010540616 A5 JP2010540616 A5 JP 2010540616A5 JP 2010527565 A JP2010527565 A JP 2010527565A JP 2010527565 A JP2010527565 A JP 2010527565A JP 2010540616 A5 JP2010540616 A5 JP 2010540616A5

Authority

JP

Japan

Prior art keywords

derivative

lag

protein

recombinant

use according

Prior art date

2008-10-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 102000017578 LAG3 Human genes 0.000 claims description 31
• 101150030213 Lag3 gene Proteins 0.000 claims description 31
• 150000001875 compounds Chemical class 0.000 claims description 10
• 230000001225 therapeutic effect Effects 0.000 claims description 7
• 230000001093 anti-cancer Effects 0.000 claims description 6
• 230000001024 immunotherapeutic effect Effects 0.000 claims description 5
• 229960005395 cetuximab Drugs 0.000 claims description 3
• 229960001776 edrecolomab Drugs 0.000 claims description 3
• 229960004641 rituximab Drugs 0.000 claims description 3
• 229960000575 trastuzumab Drugs 0.000 claims description 3
• 230000003013 cytotoxicity Effects 0.000 claims description 2
• 231100000135 cytotoxicity Toxicity 0.000 claims description 2
• 230000001419 dependent effect Effects 0.000 claims description 2
• 239000000203 mixture Substances 0.000 claims description 2
• 210000004881 tumor cell Anatomy 0.000 claims description 2
• 239000003814 drug Substances 0.000 claims 8
• 230000000973 chemotherapeutic effect Effects 0.000 claims 5
• 102000043131 MHC class II family Human genes 0.000 claims 4
• 108091054438 MHC class II family Proteins 0.000 claims 4
• 206010028980 Neoplasm Diseases 0.000 claims 4
• 201000011510 cancer Diseases 0.000 claims 4
• 239000012634 fragment Substances 0.000 claims 4
• 229940056913 eftilagimod alfa Drugs 0.000 claims 3
• 108020001507 fusion proteins Proteins 0.000 claims 3
• 102000037865 fusion proteins Human genes 0.000 claims 3
• 210000001616 monocyte Anatomy 0.000 claims 3
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
• 229940123237 Taxane Drugs 0.000 claims 2
• 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
• 239000002246 antineoplastic agent Substances 0.000 claims 2
• 230000028993 immune response Effects 0.000 claims 2
• 230000001404 mediated effect Effects 0.000 claims 2
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
• 229930012538 Paclitaxel Natural products 0.000 claims 1
• 229940044683 chemotherapy drug Drugs 0.000 claims 1
• 229940127089 cytotoxic agent Drugs 0.000 claims 1
• 229960003668 docetaxel Drugs 0.000 claims 1
• 229960004679 doxorubicin Drugs 0.000 claims 1
• 229960005277 gemcitabine Drugs 0.000 claims 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
• 238000001990 intravenous administration Methods 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 229960001592 paclitaxel Drugs 0.000 claims 1
• 238000007920 subcutaneous administration Methods 0.000 claims 1
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
• 230000002924 anti-infective effect Effects 0.000 description 1